Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26902. Epub 2017 Nov 28.

Affiliations

¹ Department of Oncology for Children and Adolescents, Gustave Roussy Caner Campus, Villejuif, France.
² Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France.
³ Department of Clinical Research, Gustave Roussy Cancer Campus, Villejuif, France.
⁴ Department of Haematology, Hôpital Saint Antoine, Paris, France.
⁵ Department of Medecine, Centre Hospitalier de la Polynésie Française, Papeete, Polynésie Française.

PMID: 29193772
DOI: 10.1002/pbc.26902

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Anaplastic Lymphoma Kinase / antagonists & inhibitors
Anaplastic Lymphoma Kinase / metabolism*
Humans
Lymphoma, Large-Cell, Anaplastic* / diagnosis
Lymphoma, Large-Cell, Anaplastic* / drug therapy
Lymphoma, Large-Cell, Anaplastic* / enzymology
Lymphoma, Large-Cell, Anaplastic* / pathology
Male
Neoplasm Proteins / antagonists & inhibitors
Neoplasm Proteins / metabolism*
Nivolumab / administration & dosage*

Substances

Neoplasm Proteins
Nivolumab
ALK protein, human
Anaplastic Lymphoma Kinase